KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $39.9 billion.

  • Teva Pharmaceutical Industries' Liabilities and Shareholders Equity fell 4.55% to $39.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $157.7 billion, marking a year-over-year decrease of 6.86%. This contributed to the annual value of $39.3 billion for FY2024, which is 9.55% down from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity is $39.9 billion, which was down 0.69% from $40.1 billion recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity peaked at $49.2 billion during Q2 2021, and registered a low of $38.4 billion during Q1 2025.
  • In the last 3 years, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity had a median value of $41.8 billion in 2024 and averaged $41.4 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity dropped by 11.43% in 2021 and then rose by 0.80% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Liabilities and Shareholders Equity (MRQ) stood at $47.7 billion in 2021, then dropped by 7.67% to $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then dropped by 9.55% to $39.3 billion in 2024, then rose by 1.35% to $39.9 billion in 2025.
  • Its last three reported values are $39.9 billion in Q3 2025, $40.1 billion for Q2 2025, and $38.4 billion during Q1 2025.